3 terminated, 2 completed, 2 recruiting, 1 active not recruiting. 4 Phase 1, 4 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Refractory Fallopian Tube Carcinoma: new trials by email Literature Review of Refractory Fallopian Tube Carcinoma trials Research Report on Refractory Fallopian Tube Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 12 | 2024-09-20 | 2026-03-16 |
| Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Irinotecan Sucrosofate - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Completed | Northwestern University | 3 | 2021-03-16 | 2023-01-19 |
| ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration - Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | Recruiting | Ira Winer | 62 | 2020-01-21 | 2026-06-17 |
| AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Batiraxcept, Durvalumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 12 | 2019-12-03 | 2025-06-11 |
| Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients Cisplatin, Cytoreductive Surgery, Doxorubicin - Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm | Early Phase 1 | Terminated | Mayo Clinic | 2 | 2019-11-08 | 2025-02-20 |
| Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer PRGN-3005 UltraCAR-T cells - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Active not recruiting | Precigen, Inc | 71 | 2019-04-30 | 2024-11-08 |
| Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cellular Therapy - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 4 | 2019-03-08 | 2024-09-19 |
| Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Durvalumab, Tremelimumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 100 | 2017-05-18 | 2026-08-05 |
Fallopian Tube Neoplasms (8) · Ovarian Neoplasms (8) · Colonic Neoplasms (1) · Desmoplastic Small Round Cell Tumor (1) · Liposarcoma (1) · Mesothelioma, Malignant (1) · Pelvic Neoplasms (1) · Rectal Neoplasms (1) · Rhabdomyosarcoma (1) · Sarcoma (1) · Stomach Neoplasms (1)
Adnexal Diseases (8) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Fallopian Tube Diseases (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genital Diseases (8) · Genital Diseases, Female (8) · Genital Neoplasms, Female (8) · Gonadal Disorders (8) · Neoplasms (8) · Neoplasms by Site (8) · Ovarian Diseases (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8)
Disulfides (3) · Immunoglobulin G (3) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · durvalumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · AVB-500 fusion protein (1) · Bendamustine Hydrochloride (1) · Bevacizumab (1) · Cell- and Tissue-Based Therapy (1) · Cisplatin (1) · Cyclophosphamide (1) · Cytoreduction Surgical Procedures (1) · Doxorubicin (1) · Esters (1)
M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · Ira Winer (1) · Northwestern University (1) · Precigen, Inc (1) · Roswell Park Cancer Institute (1)
United States (8)
Amir A Jazaeri (2) · Amy R. Lankford, PhD (1) · Brenda J. Ernst, M.D. (1) · Daniela E Matei, M.D. (1) · Emese Zsiros, MD (1) · Ira Winer, M.D. (1) · Patricio C. Gargollo, M.D. (1)
P30CA060553 (1)